Progressive Myoclonus Epilepsy Type 2

Author(s):  
Markus Braun-Falco ◽  
Henry J. Mankin ◽  
Sharon L. Wenger ◽  
Markus Braun-Falco ◽  
Stephan DiSean Kendall ◽  
...  
Seizure ◽  
2016 ◽  
Vol 42 ◽  
pp. 1-6 ◽  
Author(s):  
Roberta Opri ◽  
Gian Maria Fabrizi ◽  
Gaetano Cantalupo ◽  
Moreno Ferrarini ◽  
Alessandro Simonati ◽  
...  

2021 ◽  
Vol 22 (10) ◽  
pp. 5351
Author(s):  
Pascual Sanz ◽  
José Maria Serratosa ◽  
Marina P. Sánchez

Metformin is a drug in the family of biguanide compounds that is widely used in the treatment of type 2 diabetes (T2D). Interestingly, the therapeutic potential of metformin expands its prescribed use as an anti-diabetic drug. In this sense, it has been described that metformin administration has beneficial effects on different neurological conditions. In this work, we review the beneficial effects of this drug as a neuroprotective agent in different neurological diseases, with a special focus on epileptic disorders and Lafora disease, a particular type of progressive myoclonus epilepsy. In addition, we review the different proposed mechanisms of action of metformin to understand its function at the neurological level.


Antioxidants ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 357
Author(s):  
Mojca Trstenjak Prebanda ◽  
Petra Matjan-Štefin ◽  
Boris Turk ◽  
Nataša Kopitar-Jerala

Stefin B (cystatin B) is an inhibitor of endo-lysosomal cysteine cathepsin, and the loss-of-function mutations in the stefin B gene were reported in patients with Unverricht–Lundborg disease (EPM1), a form of progressive myoclonus epilepsy. Stefin B-deficient mice, a mouse model of the disease, display key features of EPM1, including myoclonic seizures. Although the underlying mechanism is not yet completely clear, it was reported that the impaired redox homeostasis and inflammation in the brain contribute to the progression of the disease. In the present study, we investigated if lipopolysaccharide (LPS)-triggered neuroinflammation affected the protein levels of redox-sensitive proteins: thioredoxin (Trx1), thioredoxin reductase (TrxR), peroxiredoxins (Prxs) in brain and cerebella of stefin B-deficient mice. LPS challenge was found to result in a marked elevation of Trx1 and TrxR in the brain and cerebella of stefin B deficient mice, while Prx1 was upregulated only in cerebella after LPS challenge. Mitochondrial peroxiredoxin 3 (Prx3), was upregulated also in the cerebellar tissue lysates prepared from unchallenged stefin B deficient mice, while after LPS challenge Prx3 was upregulated in stefin B deficient brain and cerebella. Our results imply the role of oxidative stress in the progression of the disease.


2014 ◽  
Vol 339 (1-2) ◽  
pp. 210-213 ◽  
Author(s):  
Marsha Zeigler ◽  
Vardiella Meiner ◽  
J.P. Newman ◽  
Bettina Steiner-Birmanns ◽  
Ruth Bargal ◽  
...  

2007 ◽  
Vol 23 (2) ◽  
pp. 240-242 ◽  
Author(s):  
Julie Turnbull ◽  
Santosh Kumar ◽  
Zhi-Ping Ren ◽  
Shanmugakonar Muralitharan ◽  
Taline Naranian ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document